-
Mashup Score: 0
Prostate cancer, PROpel trial, homologous recombination repair mutation (HRRm), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Olaparib, Abiraterone, Olaparib plus Abiraterone Versus Placebo plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer, health-related quality of life (HRQoL), health-related quality of life results from PROpel trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
Prostate cancer, PROpel trial, homologous recombination repair mutation (HRRm), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Olaparib, Abiraterone, Olaparib plus Abiraterone Versus Placebo plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer, health-related quality of life (HRQoL), health-related quality of life results from PROpel trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
Prostate cancer, PROpel trial, homologous recombination repair mutation (HRRm), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Olaparib, Abiraterone, Olaparib plus Abiraterone Versus Placebo plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer, health-related quality of life (HRQoL), health-related quality of life results from PROpel trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Patient-reported outcomes with olaparib + abiraterone vs PBO + abi for #mCRPC: a randomized, double-blind, phase 2 trial. #BeyondTheAbstract with Fred Saad, MD, FRCS @chumontreal and Noel Clarke, MBBS, ChM, FRCS @TheChristieNHS. #ReadNow on UroToday > https://t.co/r4dcS1UTHo https://t.co/QJ0rV2iesM